(Q34804897)

4 August 2017

1 reference

title

Measuring the clinical response. What does it mean? (English)

1 reference

4 August 2017

Therasse P

1

1 reference

4 August 2017

1 September 2002

1 reference

European Journal of Cancer

4 August 2017

1 reference

4 August 2017

38

1 reference

4 August 2017

1817-1823

1 reference

4 August 2017

14

1 reference

Assessment of response to therapy in advanced breast cancer: a project of the Programme on Clinical Oncology of the International Union Against Cancer, Geneva, Switzerland

4 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900182-X

7 January 2021

Reporting results of cancer treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900182-X

7 January 2021

Southwest Oncology Group standard response criteria, endpoint definitions and toxicity criteria

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900182-X

7 January 2021

Influence of measurement error on assessment of response to anticancer chemotherapy: proposal for new criteria of tumor response

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900182-X

7 January 2021

Multistage designs for phase II clinical trials: statistical issues in cancer research

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900182-X

7 January 2021

Results of an independent oncology review board of pivotal clinical trials of gemcitabine in non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900182-X

7 January 2021

Response rate accuracy in oncology trials: reasons for interobserver variability. Groupe Français d'Immunothérapie of the Fédération Nationale des Centres de Lutte Contre le Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900182-X

7 January 2021

Paclitaxel by 3-hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: high antitumor efficacy and cardiac effects in a dose-finding and sequence-finding study.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900182-X

7 January 2021

An EORTC pilot study of filgrastim (recombinant human granulocyte colony stimulating factor) as support to a high dose-intensive epiadriamycin-cyclophosphamide regimen in chemotherapy-naive patients with locally advanced or metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900182-X

7 January 2021

Measuring response in solid tumors: unidimensional versus bidimensional measurement

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900182-X

7 January 2021

Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900182-X

7 January 2021

Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900182-X

7 January 2021

Comparing survival of responders and nonresponders after treatment: a potential source of confusion in interpreting cancer clinical trials.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900182-X

7 January 2021

Surrogate end points in clinical trials: are we being misled?

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900182-X

7 January 2021

On the relationship between response to treatment and survival time

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900182-X

7 January 2021

Does chemotherapy improve survival in advanced breast cancer? A statistical overview

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900182-X

7 January 2021

Statistical model to determine the relationship of response and survival in patients with advanced ovarian cancer treated with chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900182-X

7 January 2021

A model to select chemotherapy regimens for phase III trials for extensive-stage small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900182-X

7 January 2021

Relation between tumour response to first-line chemotherapy and survival in advanced colorectal cancer: a meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900182-X

7 January 2021

Response rates, survival, and chemotherapy trials

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900182-X

7 January 2021

The pursuit of optimal outcomes in cancer therapy in a new age of rationally designed target-based anticancer agents

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900182-X

7 January 2021

10.1016/S0959-8049(02)00182-X

Identifiers

DOI

1 reference

4 August 2017

1 reference

PubMed ID

12204662